If you have been reading about AOD9604 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-04-18. Numbers and descriptions here follow the published literature rather than marketing material.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
=== Limits on number of awardees === The provision that restricts the maximum number of nominees to three for any one prize, introduced in 1968, has caused considerable controversy. From the 1950s onward, there has been an increasing trend to award the Nobel Prize in Physiology or Medicine to more than one person. There were 59 people who received the prize in the first 50 years of the last century, while 113 individuals received it between 1951 and 2000. This increase could be attributed to the rise of the international scientific community after World War II, resulting in more persons being responsible for the discovery, and nominated for, a particular prize. Also, current biomedical research is more often carried out by teams rather than by scientists working alone, making it unlikely that any one scientist, or even a few, is primarily responsible for a discovery; this has meant that a prize nomination that would have to include more than three contributors is automatically excluded from consideration. Also, deserving contributors may not be nominated at all because the restriction results in a cut-off point of three nominees per prize, leading to controversial exclusions.
Amivantamab, sold under the brand name Rybrevant, is a bispecific monoclonal antibody used to treat non-small cell lung cancer. Amivantamab is a bispecific epidermal growth factor (EGF) receptor-directed and MET receptor-directed antibody. It is the first treatment for adults with non-small cell lung cancer whose tumors have specific types of genetic mutations: epidermal growth factor receptor (EGFR) exon 20 insertion mutations. The most common side effects include rash, infusion-related reactions, skin infections around the fingernails or toenails, muscle and joint pain, shortness of breath, nausea, fatigue, swelling in the lower legs or hands or face, sores in the mouth, cough, constipation, vomiting and changes in certain blood tests. Amivantamab was approved for medical use in the United States in May 2021, and in the European Union in December 2021. The US Food and Drug Administration considers it to be a first-in-class medication.
After the prey has been digested, the cone snail will regurgitate any indigestible material, such as spines and scales, along with the harpoon. There is always a radular tooth in the radular sac. A tooth may also be used in self-defense when the snail feels threatened. The harpoon attack of the species Conus catus has been found to be one of the fastest complete movements recorded in animals, with a maximum speed of 90 km/h (56 mph), an acceleration of 400,000 m/s2, and a deceleration of 700,000 m/s2. The speed of other animals such as the peacock mantis shrimp and the trap-jaw ant was measured at the free end of a fixed appendage, while the speed of the harpoon was measured from its base and traveling inside the proboscis. The reason for this speed relies in hydrostatic pressure by the fluid inside the proboscis which propels the harpoon inside until it is almost completely out. A sphincter acts as a valve to keep fluid in the proximal half and in the distal half a constriction of ephitelial tissue together with a thicker harpoon base helps to build up hydrostatic pressure when the sphincter opens. The deceleration may help release the venom from the harpoon.
== Pharmacology == Infliximab is a purified, recombinant DNA-derived chimeric human-mouse IgG monoclonal antibody that consists of mouse heavy and light chain variable regions combined with human heavy and light chain constant regions. It has a serum half-life of 9.5 days and can be detected in serum 8 weeks after infusion treatment. Infliximab neutralizes the biological activity of TNF by binding with high affinity to the soluble (free floating in the blood) and transmembrane (located on the outer membranes of T cells and similar immune cells) forms of TNF, and inhibits or prevents the effective binding of TNF with its receptors. Infliximab and adalimumab (another TNF antagonist) are in the subclass of "anti-TNF antibodies" (they are in the form of naturally occurring antibodies), and are capable of neutralizing all forms (extracellular-, transmembrane-, and receptor-bound) of TNF. Etanercept, a third TNF antagonist, is in a different subclass (receptor-construct fusion protein), and, because of its modified form, cannot neutralize receptor-bound TNF. Additionally, the anti-TNF antibodies adalimumab and infliximab have the capability of lysing cells involved in the inflammatory process, whereas the receptor fusion protein apparently lacks this capability. Other monoclonal antibodies targeting TNF are golimumab, adalimumab, and certolizumab pegol. Etanercept also binds and inhibits the action of TNF, but is not a monoclonal antibody (it is instead a fusion of TNF-receptor and an antibody constant region).
=== United States === In the United States, the U.S. Department of Agriculture (USDA) is responsible for that oversight. To comply with USDA regulations, poultry jerky must be heated to an internal temperature of 71 °C (160 °F) for uncured poultry or 68 °C (155 °F) for cured poultry to be considered safe.
Sources: en.wikipedia.org
In the 1920s there was an outbreak of a mysterious haemorrhagic cattle disease in Canada and the northern United States. The disease was named sweet clover disease because the cattle had grazed on sweet clover hay. It wasn't until ten years after the outbreak, that a local investigator, Karl P. Link and his student Wilhelm Schoeffel started an intense investigation to find the substance causing the internal bleeding. It took them 6 years to discover dicoumarol, the causing agent. They patented the right for the substance and in 1945 Link started selling a coumarin derivative as a rodenticide. He and his colleagues worked on several variations and ended up with a substance they named warfarin in 1948. It wasn't until 1954 that it was approved for medicinal use in humans making warfarin the first oral anticoagulant drug.
Rimexolone is a glucocorticoid steroid used to treat inflammation in the eye. It is marketed as a 1% eye drop suspension under the trade name Vexol by Alcon Laboratories, but was discontinued in the US and other countries.
In the morning of 8 October, Hezbollah fired rockets and shells at the Shebaa Farms region in support of Hamas's attack onto Israel; in response, the Israel Defense Forces (IDF) fired artillery shells and a drone into southern Lebanon. Two Lebanese children were reportedly injured by broken glass. The next day, Israel exchanged a series of airstrikes on southern Lebanon near the towns of Marwahin, Ayta ash Shab and Dhayra in the Bint Jbeil district. This was after numerous Palestinian militants infiltrated the Israeli border, which Hezbollah denied involvement with. The Palestinian Islamic Jihad militia claimed responsibility for the armed infiltration. The IDF killed at least two perpetrators (likely Palestinians), while a third returned to Lebanon. A Hezbollah media source announced three of Hezbollah's members died in the IDF retaliation. Hezbollah fired rockets and artillery in retaliation. During the clashes, two Israeli soldiers and Lt. Col Alim Abdallah, Deputy Commander of the IDF's 300th Brigade, were killed and another three were wounded. On 11 October, Hezbollah fired anti-tank missiles at an IDF position and claimed to have produced casualties. In response, the IDF shelled the area where the attack was launched. The Lebanese-Italian hospital in Tyre admitted three injured civilians. The IDF ordered residents of northern Israel to seek shelter following reports of drones being launched from southern Lebanon. A Patriot missile was launched to intercept a suspicious projectile, after which the IDF found that the object in question was not a drone.
In 1995, Messina Denaro, who by then had a daughter from a previous relationship with Francesca Alagna, went to live with his mother. In a letter addressed to a friend, seized by investigators, Messina Denaro revealed that he had never met this daughter. In 1999, Messina Denaro received his first life sentence, in absentia for the murder of Giuseppe Montalto, a prison guard at the Ucciardone prison in Palermo, killed in 1995. In 2000, Messina Denaro received a life sentence in absentia for the 1993 bomb attacks in Florence, Milan and Rome, and another life sentence later that year. In 2000, Maria Mesi was arrested, and because police found love letters that she had exchanged with Messina Denaro, the following year she was sentenced to three years in prison for aiding and abetting together with her brother Francesco. In July 2006, investigators found other love letters from Maria Mesi at the home of Filippo Guttadauro, who had the task of delivering them to his brother-in-law Messina Denaro. In 2003, Messina Denaro was given another life sentence in absentia, accused of hundreds of murders which occurred in the early 1990s during the Alcamo mafia feud fought between the Corleonesi and the Stiddaro clan of the Greco Mafia clan.
=== Pregnancy === Methocarbamol is labeled by the FDA as a pregnancy category C medication. The teratogenic effects of the medication are not known and it should be given to pregnant women only when indicated.
Sources: en.wikipedia.org
Alpha-glucosidase inhibitors (AGIs) are oral anti-diabetic drugs used for diabetes mellitus type 2 that work by preventing the digestion of carbohydrates (such as starch and table sugar). Naturally occurring AGIs are found in raw plants/herbs such as cinnamon and white mulberry as well as some bacteria. Carbohydrates are normally converted into simple sugars (monosaccharides) by alpha-glucosidase enzymes present on cells lining the intestine, enabling monosaccharides to be absorbed through the intestine. Hence, alpha-glucosidase inhibitors reduce the impact of dietary carbohydrates on blood sugar.
== Medicinal value == As far back as ancient times, Pliny the Elder had recognised that dried cherries have a diuretic effect; he mentioned them briefly in his description of medicinal plants found in books XX-XXVII of the Naturalis Historia.
== Production == Artificial nanoparticles can be created from any solid or liquid material, including metals, dielectrics, and semiconductors. They may be internally homogeneous or heterogenous, e.g. with a core–shell structure. There are several methods for creating nanoparticles, including gas condensation, attrition, chemical precipitation, ion implantation, pyrolysis, hydrothermal synthesis, and biosynthesis.
== Diagnosis == The diagnosis is based on involvement of less than 10% of the skin. It is known as TEN when more than 30% of the skin is involved and an intermediate form with 10 to 30% involvement. A positive Nikolsky's sign is helpful in the diagnosis of SJS and TEN. A skin biopsy is helpful, but not required, to establish a diagnosis of SJS and TEN.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.